Keywords: Eli Lilly, 2012 forecasts, Zyprexa
Eli Lilly falls as 2012 forecasts disappoint
Article | 06 January 2012
US drug major Eli Lilly (NYSE: LLY) saw its shares fall 2.6% to 39.66 in mid-morning trading yesterday, after the company ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
